Historical Investment Performance in Top 1% of Venture Funds. Primary focus on Longevity and defeating Diseases of Aging.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Thynk Capital possess a historical investment performance in the top 1% of venture capital. Focused on investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer&s;s, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10%/year.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2021 | iviva medical | Seed Round | - |
7/2013 | Lubris BioPharma | Series A | - |
7/2016 | Curtana Pharmaceuticals | Convertible Note | - |
5/2019 | Viscient Biosciences | Seed Round | - |
11/2018 | Elicio Therapeutics | Venture Round | - |
3/2018 | Marina Biotech | Post-IPO Equity | - |
12/2017 | Theragene Pharmaceuticals | Convertible Note | - |
5/2019 | Repair Biotechnologies | Seed Round | 0 |
11/2017 | KLOTHO Therapeutics, Inc. | Series A | 10M |
4/2019 | X-Vax Technology | Series A | - |
2/2018 | Elevian | Convertible Note | 2.9M |
11/2017 | X4 Pharmaceuticals | Series A | - |
9/2017 | Fisker | Series A | - |
4/2019 | Repair Biotechnologies | Convertible Note | - |
6/2018 | KitoTech Medical | Convertible Note | - |
2/2015 | WinSanTor, Inc. | Series A | - |
8/2021 | IMX | Seed Round | - |
8/2021 | IMX | Seed Round | - |
3/2021 | iviva medical | Seed Round | - |
5/2019 | Viscient Biosciences | Seed Round | - |
5/2019 | Repair Biotechnologies | Seed Round | 0 |
4/2019 | X-Vax Technology | Series A | - |
4/2019 | Repair Biotechnologies | Convertible Note | - |
11/2018 | Elicio Therapeutics | Venture Round | - |
6/2018 | KitoTech Medical | Convertible Note | - |
3/2018 | Marina Biotech | Post-IPO Equity | - |
2/2018 | Elevian | Convertible Note | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|